Reply to thread

[ATTACH=full]9736[/ATTACH]

[ATTACH=full]9737[/ATTACH]

Most of the guidelines in Table 1 share the context in regard to cardiovascular risk, development of prostate cancer, and infertility. The safety of testosterone therapy in patients with treated prostate cancer has been on the rise in recent decades. The relationship between testosterone treatment and the development of prostate cancer is conclusive in 5 studies in Table 1. In terms of saturation theory [10], prostate cancer (and benign prostate hyperplasia) is suppressed in only the castrated level of testosterone; vice versa, testosterone therapy in TD may neither aggravate prostate cancer (and prostate-related lower urinary tract symptoms) nor cause prostate cancer. For the same reason, the EAU and ISSM guidelines clarified the possibility of testosterone therapy in patients with treated prostate cancer. Most researchers in urology agreed with this concept because all patients scheduled in prostatectomy should undergo bilateral orchiectomies if testosterone is responsible for developing prostate cancer.

Reference: Efficacy and Safety of Testosterone Therapy Based on Guideline Recommendations; Re: Clinical Practice Guideline by the American College of Physicians